No Data
Express News | RBC Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $54
Intellia Therapeutics Analyst Ratings
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully
Evercore ISI Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
Intellia Therapeutics: A Strong Buy on Groundbreaking Gene Editing Advances and Positive Clinical Trials
RBC Cuts Price Target on Intellia Therapeutics to $54 From $60, Keeps Outperform, Speculative Risk
10baggerbamm : why is anybody even bothering with this woman she's been negative year-to-date she is no conviction she gives price targets pie in the sky and if she really believed in them she would not be selling these companies she's full of shit she made money one year one time everything else has been a disaster
tankeng : yes this woman has problems and arrogant
OhNowGombie : Another quack you mean? Totally out of her gourd too